Tango Therapeutics (TNGX) Equity Average (2020 - 2026)

Tango Therapeutics' Equity Average history runs 7 years deep, the most recent figure standing at $368.8 million for Q1 2026.

• In Q1 2026, Equity Average rose 101.4% year-over-year to $368.8 million; the TTM figure through Mar 2026 stood at $368.8 million (up 101.4% YoY), while the FY2025 annual figure was $272.8 million, up 20.56% from the prior year.
• Equity Average was $368.8 million for Q1 2026 at Tango Therapeutics, up from $253.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $368.8 million in Q1 2026 to a low of $147.5 million in Q3 2025.
• Historically, Equity Average has averaged $248.7 million across 5 years, with a median of $253.1 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 589.29% in 2022, then plunged 41.09% in 2025.
• A 5-year view of Equity Average shows it stood at $261.3 million in 2022, then grew by 1.37% to $264.9 million in 2023, then retreated by 19.07% to $214.3 million in 2024, then grew by 18.08% to $253.1 million in 2025, then surged by 45.73% to $368.8 million in 2026.
• The last three Equity Average figures came in at $368.8 million (Q1 2026), $253.1 million (Q4 2025), and $147.5 million (Q3 2025), per Business Quant data.